Try our mobile app

Switch to company model in classical logic    *

General information

Country: SWITZERLAND

Sector: Biotechnology

CRISPR Therapeutics AG is a bio-technology company. The Company researches, develops, and manufactures biological transformative gene-based medicines and other related products. CRISPR Therapeutics operates in Switzerland.
Website: crisprtx.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 33.4%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -8.2%

Profitability: LTM EBITDA margin is negative, -5 138.5%. Gross margin is low, -10 000.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.28 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 23.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 107.1% higher than minimum and 27.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -247.7x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $51.4 mln (1.264% of cap.)

Key Financials (Download financials)

Ticker: CRSP
Share price, USD:  (-2.0%)64.76
year average price 44.94  


year start price 57.92 2024-07-27

min close price 31.27 2025-04-08

max close price 68.14 2025-07-23

current price 64.76 2025-07-26
Common stocks: 78 021 520

Dividend Yield:  0.0%
EV / Sales: 236.9x
Margin (EBITDA LTM / Revenue): -5 138.5%
Fundamental value created in LTM:
Market Cap ($m): 5 053
Net Debt ($m): -1 973
EV (Enterprise Value): 3 080
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-25zacks.com

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

2025-07-21fool.com

3 Monster Stocks in the Making to Buy Right Now

2025-07-10zacks.com

CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?

2025-07-02fool.com

2 Growth Stocks to Buy Hand Over Fist in July

2025-06-25zacks.com

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

2025-06-23youtube.com

The Big 3: CRSP, OKLO, GME

2025-06-21fool.com

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

2025-06-19zacks.com

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

2025-06-18zacks.com

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

2025-06-15247wallst.com

Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-05 2024-05-08 2024-02-21 2023-11-06 2023-08-07 2023-05-08 2023-02-21 2022-11-01
acceptedDate 2024-11-05 09:10:55 2024-08-05 16:10:26 2024-05-08 16:20:38 2024-02-21 07:50:50 2023-11-06 16:42:03 2023-08-07 16:12:38 2023-05-08 16:11:26 2023-02-21 16:11:51 2022-11-01 16:12:27
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 602 000 517 000 504 000 200M 0 70M 100M 6000 94 000
costOfRevenue 11M 57M 52M 20M 23M 45M 42M 7M 39M
grossProfit -11M -56M -51M 180M -23M 25M 58M -7M -39M
grossProfitRatio -17.527 -109.205 -101.776 0.9 0 0.362 0.578 -1136.167 -412.394
researchAndDevelopmentExpenses 82M 75M 71M 95M 91M 102M 100M 104M 117M
generalAndAdministrativeExpenses 17M 19M 18M 16M 18M 19M 22M 21M 27M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 17M 19M 18M 16M 18M 19M 22M 21M 27M
otherExpenses 0 26M 25M 20M 21M 18M 13M 11M 0
operatingExpenses 100M 95M 89M 110M 109M 121M 122M 125M 144M
costAndExpenses 111M 152M 141M 130M 132M 165M 164M 132M 182M
interestIncome 0 0 0 -52M 21M 0 0 0 0
interestExpense 0 0 0 18M 0 0 -18M -17M -7M
depreciationAndAmortization 5M 5M 5M 43 812 5M 5M 5M 6M 5M
ebitda -105M -146M -136M 74M -132M -90M -64M -132M -177M
ebitdaratio -175.068 -283.201 -269.353 0.372 0 -1.289 -0.645 -21 924 -1886.915
operatingIncome -110M -151M -141M 70M -132M -95M -64M -132M -182M
operatingIncomeRatio -182.94 -292.573 -278.942 0.348 0 -1.36 -0.645 -21 924 -1940.298
totalOtherIncomeExpensesNet 25M 26M 25M 20M 21M 18M 13M 11M 7M
incomeBeforeTax -85M -125M -116M 90M -112M -77M -52M -120M -175M
incomeBeforeTaxRatio -141.306 -242.014 -229.895 0.448 0 -1.097 -0.517 -20 009 -1863.021
incomeTaxExpense 876 000 1M 724 000 233 000 -412 000 923 000 1M -9M -575 000
netIncome -86M -126M -117M 89M -112M -78M -53M -111M -175M
netIncomeRatio -142.761 -244.503 -231.331 0.447 0 -1.111 -0.531 -18 429 -1856.904
eps -1.01 -1.49 -1.43 1.12 -1.41 -0.98 -0.67 -1.41 -2.24
epsdiluted -1.01 -1.49 -1.43 1.1 -1.41 -0.98 -0.67 -1.41 -2.24
weightedAverageShsOut 85M 85M 82M 80M 79M 79M 79M 78M 78M
weightedAverageShsOutDil 85M 85M 82M 81M 79M 79M 79M 78M 78M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-05 2024-05-08 2024-02-21 2023-11-06 2023-08-07 2023-05-08 2023-02-21 2022-11-01
acceptedDate 2024-11-05 09:10:55 2024-08-05 16:10:26 2024-05-08 16:20:38 2024-02-21 07:50:50 2023-11-06 16:42:03 2023-08-07 16:12:38 2023-05-08 16:11:26 2023-02-21 16:11:51 2022-11-01 16:12:27
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 226M 484M 707M 389M 528M 445M 344M 212M 494M
shortTermInvestments 1 710M 1 517M 1 401M 1 304M 1 212M 1 323M 1 539M 1 603M 1 402M
cashAndShortTermInvestments 1 936M 2 002M 2 108M 1 694M 1 740M 1 768M 344M 1 815M 1 896M
netReceivables 0 0 0 200M 0 70M 0 0 49 000
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 8M 9M 11M 14M 21M 21M 25M 38M 37M
totalCurrentAssets 1 944M 2 010M 2 120M 1 908M 1 761M 1 860M 1 908M 1 853M 1 933M
propertyPlantEquipmentNet 285M 292M 299M 306M 312M 319M 316M 321M 328M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 2000 16 000 30 000 43 000 57 000 71 000 84 000
goodwillAndIntangibleAssets 0 0 2000 16 000 30 000 43 000 57 000 71 000 84 000
longTermInvestments 0 23M 12M 2M 12M 5M 6M 53M 77M
taxAssets 0 0 -12M 0 -12M 0 0 0 0
otherNonCurrentAssets 27M 15M 21M 14M 14M 14M 14M 16M 16M
totalNonCurrentAssets 312M 329M 319M 321M 326M 337M 336M 390M 421M
otherAssets 0 0 1 0 0 0 0 0 0
totalAssets 2 256M 2 340M 2 439M 2 230M 2 087M 2 197M 2 244M 2 243M 2 353M
accountPayables 16M 9M 16M 38M 26M 28M 45M 27M 32M
shortTermDebt 34M 33M 16M 16M 15M 15M 16M 16M 11M
taxPayables 838 000 454 000 1M 438 000 176 000 558 000 273 000 135 000 4M
deferredRevenue 4M 5M 4M 4M 4M 12M 12M 12M 12M
otherCurrentLiabilities 35M 80M 82M 51M 67M 78M 74M 66M 95M
totalCurrentLiabilities 90M 128M 119M 109M 111M 133M 147M 121M 151M
longTermDebt 211M 215M 219M 223M 227M 230M 225M 228M 231M
deferredRevenueNonCurrent 12M 13M 14M 14M 16M 12M 12M 12M 12M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 4M 4M 4M 958 000 5M 5M 6M 6M 193M
totalNonCurrentLiabilities 227M 231M 236M 238M 248M 248M 243M 246M 249M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 228M 231M 219M 239M 242M 245M 240M 244M 242M
totalLiabilities 316M 359M 355M 347M 359M 381M 389M 368M 399M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 3M 3M 3M 2M 2M 2M 2M 2M 2M
retainedEarnings -1 329M -1 243M -1 116M -1 000M -1 089M -977M -899M -846M -736M
accumulatedOtherComprehensiveIncomeLoss 11M -3M -2M 2M -7M -9M -9M -16M -22M
othertotalStockholdersEquity 3 255M 3 224M 3 199M 2 878M 2 821M 2 799M 2 761M 2 735M 2 709M
totalStockholdersEquity 1 940M 1 981M 2 084M 1 883M 1 728M 1 816M 1 855M 1 875M 1 954M
totalEquity 1 940M 1 981M 2 084M 1 883M 1 728M 1 816M 1 855M 1 875M 1 954M
totalLiabilitiesAndStockholdersEquity 2 256M 2 340M 2 439M 2 230M 2 087M 2 197M 2 244M 2 243M 2 353M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 256M 2 340M 2 439M 2 230M 2 087M 2 197M 2 244M 2 243M 2 353M
totalInvestments 1 710M 1 540M 1 412M 1 306M 1 212M 1 328M 1 545M 1 657M 1 479M
totalDebt 228M 231M 235M 239M 242M 245M 240M 244M 242M
netDebt 2M -253M -473M -151M -286M -200M -104M 32M -252M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP CRSP
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-05 2024-08-05 2024-05-08 2024-02-21 2023-11-06 2023-08-07 2023-05-08 2023-02-21 2022-11-01
acceptedDate 2024-11-05 09:10:55 2024-08-05 16:10:26 2024-05-08 16:20:38 2024-02-21 07:50:50 2023-11-06 16:42:03 2023-08-07 16:12:38 2023-05-08 16:11:26 2023-02-21 16:11:51 2022-11-01 16:12:27
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -86M -126M -117M 89M -112M -78M -53M -111M -175M
depreciationAndAmortization 5M 5M 5M 5M 5M 5M 5M 6M 5M
deferredIncomeTax 0 0 0 0 0 0 0 0 0
stockBasedCompensation 22M 24M 19M 18M 20M 22M 21M 23M 25M
changeInWorkingCapital -40M 10M 210M -204M 53M -79M 37M -32M 37M
accountsReceivables 0 0 200M -200M 70M -70M 0 49 000 17 000
inventory 0 0 0 9M 25M 12M 0 0 0
accountsPayables -38M 9M 9M -9M -25M -12M 25M -3M 0
otherWorkingCapital -2M 1M 1M -4M -17M 2M 12M -29M 37M
otherNonCashItems -7M 16M -189M -5M -5M -3M -969 000 219 000 3M
netCashProvidedByOperatingActivities -107M -96M 110M -96M -40M -133M 9M -113M -105M
investmentsInPropertyPlantAndEquipment -219 000 -707 000 -721 000 -738 000 -2M -4M -3M -6M -6M
acquisitionsNet 0 0 0 81M 0 0 0 0 0
purchasesOfInvestments -389M -476M -334M -368M -245M -187M -266M -494M -326M
salesMaturitiesOfInvestments 248M 350M 237M 287M 370M 409M 387M 325M 420M
otherInvestingActivites -20M -126M -8M -81M -1 000 000 -2M 0 0 0
netCashUsedForInvestingActivites -162M -127M -98M -81M 121M 217M 118M -176M 87M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 6M -1M 306M 33M 2M 17M 0 -970 000 970 000
commonStockRepurchased 466 000 -466 000 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 4M 546 000 306M 6M 2M 0 5M 3M 14M
netCashUsedProvidedByFinancingActivities 10M -466 000 306M 39M 2M 17M 5M 2M 15M
effectOfForexChangesOnCash 75 000 2000 -11 000 61 000 -48 000 28 000 32 000 115 000 -100 000
netChangeInCash -247M -223M 318M -139M 83M 100M 132M -286M -3M
cashAtEndOfPeriod 237M 484M 707M 401M 540M 457M 356M 224M 510M
cashAtBeginningOfPeriod 484M 707M 389M 540M 457M 356M 224M 510M 513M
operatingCashFlow -107M -96M 110M -96M -40M -133M 9M -113M -105M
capitalExpenditure -219 000 -707 000 -721 000 -738 000 -2M -4M -3M -6M -6M
freeCashFlow -107M -96M 109M -97M -42M -137M 6M -120M -111M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-05 14:01 ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
2024-08-05 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
2024-05-29 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2024-05-23 12:00 ET
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
2024-05-09 12:30 ET
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
2024-05-08 20:00 ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
2024-05-08 11:00 ET
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
2024-04-22 20:30 ET
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
2024-04-03 12:00 ET
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
2024-04-01 12:00 ET
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
2024-03-13 12:30 ET
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
2024-02-21 12:30 ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-15 13:30 ET
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
2024-02-13 13:30 ET
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
2024-02-13 13:30 ET
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
2024-02-13 07:30 ET
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
2024-01-16 21:01 ET
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
2024-01-08 12:00 ET
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
2024-01-03 13:30 ET
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-04 21:15 ET
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
2023-11-06 21:15 ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-06 10:01 ET
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
2023-10-31 21:53 ET
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
2023-10-31 11:05 ET
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
2023-10-16 12:00 ET
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
2023-09-27 13:01 ET
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
2023-09-07 12:30 ET
CRISPR Therapeutics Announces Leadership Transition
2023-08-30 12:00 ET
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
2023-08-07 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-06-13 13:00 ET
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-08 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
2023-05-02 12:00 ET
CRISPR Therapeutics to Participate Upcoming Investor Conferences
2023-04-13 20:01 ET
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
2023-04-03 12:00 ET
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023-03-29 12:00 ET
CRISPR Therapeutics Announces Departure of Board Member
2023-03-27 12:00 ET
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
2023-03-14 22:02 ET
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
2023-03-13 20:15 ET
CRISPR Therapeutics Announces Transition of Chief Financial Officer
2023-02-27 13:00 ET
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
2023-02-21 21:01 ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-08 13:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2023-01-11 13:00 ET
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
2022-12-19 13:30 ET
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
2022-12-12 15:00 ET
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
2022-12-10 13:00 ET
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
2022-12-01 13:00 ET
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
2022-11-10 22:40 ET
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
2022-11-03 13:06 ET
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
2022-11-01 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
2022-10-27 12:30 ET
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
2022-10-05 12:05 ET
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
2022-09-29 12:00 ET
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
2022-09-28 12:00 ET
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
2022-09-27 11:29 ET
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
2022-08-31 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2022-08-08 12:00 ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
2022-06-11 15:00 ET
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
2022-06-11 07:00 ET
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
2022-06-08 12:00 ET
CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-02 14:05 ET
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
2022-05-31 12:00 ET
CRISPR Therapeutics to Host Innovation Day on June 21, 2022
2022-05-16 20:01 ET
CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer
2022-05-12 14:33 ET
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress
2022-05-09 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
2022-05-04 12:00 ET
CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference
2022-04-12 20:01 ET
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
2022-04-07 20:01 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2022-03-08 21:35 ET
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual Meeting
2022-02-28 13:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2022-02-15 21:01 ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-09 13:00 ET
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022-02-02 13:30 ET
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
2021-11-23 13:30 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2021-11-22 13:30 ET
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies
2021-11-16 13:30 ET
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
2021-11-03 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
2021-11-02 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2021-10-14 11:00 ET
CRISPR Therapeutics Announces Transition of Chief Financial Officer
2021-10-12 20:01 ET
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies
2021-10-05 20:05 ET
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
2021-10-01 12:00 ET
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
2021-09-28 12:00 ET
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
2021-08-05 12:00 ET
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
2021-07-29 20:30 ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
2021-06-15 11:15 ET
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia  
2021-06-11 07:05 ET
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
2021-05-25 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2021-05-12 15:00 ET
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
2021-05-06 20:01 ET
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
2021-04-29 12:30 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2021-04-28 20:01 ET
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
2021-04-27 20:01 ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
2021-04-20 11:15 ET
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
2021-04-10 12:31 ET
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
2021-04-06 12:00 ET
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
2021-03-10 22:03 ET
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
2021-03-03 13:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2021-02-16 21:01 ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-05 13:00 ET
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
2021-02-01 13:00 ET
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
2020-12-14 13:00 ET
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
2020-12-05 17:30 ET
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
2020-11-24 13:00 ET
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-16 13:00 ET
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
2020-11-04 14:15 ET
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
2020-10-28 12:00 ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
2020-10-21 11:00 ET
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies
2020-10-07 13:26 ET
CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry
2020-09-29 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2020-09-22 13:00 ET
CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
2020-09-03 12:00 ET
CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
2020-07-30 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2020-07-27 20:30 ET
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
2020-07-01 01:29 ET
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
2020-06-29 20:01 ET
CRISPR Therapeutics Announces Proposed Offering of Common Shares
2020-06-25 12:00 ET
CRISPR Therapeutics Announces the Build-Out of New Cell Therapy Manufacturing Facility
2020-06-12 06:30 ET
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
2020-05-26 12:30 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2020-05-15 12:30 ET
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting
2020-05-14 13:02 ET
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
2020-05-11 13:00 ET
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
2020-05-07 12:00 ET
CRISPR Therapeutics to Present at the Bank of America Securities 2020 Health Care Conference
2020-04-28 20:45 ET
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
2020-02-26 21:05 ET
CRISPR Therapeutics Proposes Changes to the Board of Directors
2020-02-12 21:05 ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
2020-01-06 21:05 ET
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
2019-11-27 12:00 ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
2019-11-21 02:18 ET
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
2019-11-19 21:14 ET
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
2019-11-19 12:00 ET
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
2019-10-28 11:00 ET
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
2019-10-15 11:00 ET
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
2019-10-01 11:00 ET
CRISPR Therapeutics to Present at Upcoming Investor Conferences
2019-09-17 11:00 ET
CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019
2019-04-16 11:00 ET
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia
2019-04-01 11:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2019-03-06 12:00 ET
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
2019-02-27 21:53 ET
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting
2019-02-25 13:02 ET
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

SEC forms

Show financial reports only

SEC form 8
2025-05-19 20:36 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 8
2025-05-19 20:36 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 8
2025-05-19 20:36 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 10
2025-05-06 20:10 ET
CRISPR Therapeutics reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
CRISPR Therapeutics reported for 2025 q1
SEC form 8
2025-05-06 00:00 ET
CRISPR Therapeutics published news for 2025 q1
SEC form 8
2025-05-06 00:00 ET
CRISPR Therapeutics reported for 2025 q1
SEC form 10
2025-02-11 21:10 ET
CRISPR Therapeutics reported for 2024 q4
SEC form 10
2025-02-11 00:00 ET
CRISPR Therapeutics reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
CRISPR Therapeutics published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
CRISPR Therapeutics reported for 2024 q4
SEC form 10
2024-11-05 09:10 ET
CRISPR Therapeutics reported for 2024 q3
SEC form 8
2024-11-05 09:05 ET
CRISPR Therapeutics published news for 2024 q3
SEC form 8
2024-11-05 09:05 ET
CRISPR Therapeutics reported for 2024 q3
SEC form 10
2024-08-05 16:10 ET
CRISPR Therapeutics reported for 2024 q2
SEC form 8
2024-08-05 16:05 ET
CRISPR Therapeutics published news for 2024 q2
SEC form 8
2024-08-05 16:05 ET
CRISPR Therapeutics reported for 2024 q2
SEC form 10
2024-08-05 00:00 ET
CRISPR Therapeutics reported for 2024 q2
SEC form 10
2024-05-08 16:20 ET
CRISPR Therapeutics reported for 2024 q1
SEC form 8
2024-05-08 16:15 ET
CRISPR Therapeutics published news for 2024 q1
SEC form 8
2024-05-08 16:15 ET
CRISPR Therapeutics reported for 2024 q1
SEC form 10
2024-05-08 00:00 ET
CRISPR Therapeutics reported for 2024 q1
SEC form 10
2024-02-21 07:50 ET
CRISPR Therapeutics reported for 2023 q4
SEC form 8
2024-02-21 07:45 ET
CRISPR Therapeutics published news for 2023 q4
SEC form 8
2024-02-21 07:45 ET
CRISPR Therapeutics reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
CRISPR Therapeutics reported for 2023 q4
SEC form 10
2023-11-06 16:42 ET
CRISPR Therapeutics reported for 2023 q3
SEC form 8
2023-11-06 16:33 ET
CRISPR Therapeutics published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
CRISPR Therapeutics reported for 2023 q3
SEC form 10
2023-08-07 16:12 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 6
2023-08-07 16:07 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
CRISPR Therapeutics reported for 2023 q2
SEC form 6
2023-06-09 17:56 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 16:29 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 07:07 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
CRISPR Therapeutics reported for 2023 q1
SEC form 8
2023-05-08 00:00 ET
CRISPR Therapeutics reported for 2023 q1
SEC form 6
2023-04-03 08:10 ET
CRISPR Therapeutics published news for 2023 q1
SEC form 6
2023-03-29 08:08 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 6
2023-03-27 08:08 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 6
2023-03-14 17:42 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 6
2023-03-14 08:15 ET
CRISPR Therapeutics published news for 2022 q4
SEC form 10
2023-02-21 16:11 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 6
2023-02-21 16:06 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 10
2023-02-21 00:00 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
CRISPR Therapeutics reported for 2022 q4
SEC form 10
2022-11-01 16:12 ET
CRISPR Therapeutics published news for 2022 q3
SEC form 6
2022-11-01 16:05 ET
CRISPR Therapeutics published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
CRISPR Therapeutics reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
CRISPR Therapeutics reported for 2022 q3
SEC form 6
2022-10-27 08:36 ET
CRISPR Therapeutics published news for 2022 q3
SEC form 6
2022-09-27 07:48 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:39 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:36 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-18 17:33 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 10
2022-08-08 08:11 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 6
2022-08-08 08:05 ET
CRISPR Therapeutics published news for 2022 q2
SEC form 10
2022-08-08 00:00 ET
CRISPR Therapeutics reported for 2022 q2
SEC form 8
2022-08-08 00:00 ET
CRISPR Therapeutics reported for 2022 q2
SEC form 6
2022-06-21 17:05 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 16:58 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 08:02 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:44 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:43 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:41 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:39 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:36 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:35 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 17:33 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-23 17:41 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 16:14 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 16:05 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 10
2022-05-09 16:12 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 16:06 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
CRISPR Therapeutics reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
CRISPR Therapeutics reported for 2022 q1
SEC form 6
2022-04-25 16:23 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 6
2022-04-12 16:28 ET
CRISPR Therapeutics published news for 2022 q1
SEC form 10
2022-02-15 16:14 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 6
2022-02-15 16:05 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 10
2022-02-15 00:00 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
CRISPR Therapeutics published news for 2021 q4
SEC form 6
2021-12-20 08:00 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-11-22 08:42 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 16:11 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-11-03 16:07 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-10-14 07:15 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 6
2021-10-12 16:46 ET
CRISPR Therapeutics published news for 2021 q3
SEC form 10
2021-07-29 16:44 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 6
2021-07-29 16:34 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
CRISPR Therapeutics published news for 2021 q2
SEC form 6
2021-06-14 17:32 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-06-14 16:52 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 07:10 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-06-02 09:16 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:14 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 10
2021-04-27 16:19 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 16:05 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 10
2021-04-27 00:00 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 07:22 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 6
2021-04-05 16:18 ET
CRISPR Therapeutics published news for 2021 q1
SEC form 10
2021-02-16 16:14 ET
CRISPR Therapeutics published news for 2020 q4
SEC form 6
2021-02-16 16:06 ET
CRISPR Therapeutics published news for 2020 q4
SEC form 6
2021-01-15 16:12 ET
CRISPR Therapeutics published news for 2020 q4
SEC form 6
2020-12-17 09:06 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-12-11 08:16 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 07:50 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 09:14 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 10
2020-10-28 08:08 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 08:03 ET
CRISPR Therapeutics published news for 2020 q3
SEC form 6
2020-10-21 08:58 ET
CRISPR Therapeutics published news for 2020 q3